# TQB2102

Source: https://onco.cc/drugs/tqb2102/  
OnCo record `tqb2102` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TQB2102 is an experimental antibody-drug conjugate from Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical in phase 3 trials for HR-positive / HER2-negative breast cancer, HER2-positive breast cancer and biliary tract cancer, aimed at HER2.

## Summary

TQB2102 is an antibody-drug conjugate developed by Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical and Chia Tai Tianqing Pharmaceutical. Its target is HER2 (the sponsor names HER2). The sponsor states: Described on the study page as a next-generation HER2 antibody-drug conjugate carrying the small-molecule toxin TQ22723. ClinicalTrials.gov describes the intervention as: TQB2102 is a next-generation HER2 Antibody-Drug Conjugate drug proposed for patients with HER2 positive Recurrent/Metastatic Breast Cancer. It is the investigational product in 8 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07003074 (A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer), NCT06561607 (A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer) and NCT07008976 (Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer), in HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, biliary tract cancer and non-small-cell lung cancer. The largest, NCT07003074, plans to enrol 642 participants with primary completion expected 2029-07. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: ADC
- Mechanism: Described on the study page as a next-generation HER2 antibody-drug conjugate carrying the small-molecule toxin TQ22723.

## Sources

- ClinicalTrials.gov: trials of TQB2102: https://clinicaltrials.gov/search?intr=TQB2102

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [HER2](https://onco.cc/targets/her2/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)
- trials: [A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer](https://onco.cc/trials/nct07043725/), [A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer](https://onco.cc/trials/nct07003074/), [A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality](https://onco.cc/trials/nct06496490/), [A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer](https://onco.cc/trials/nct06561607/), [A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer](https://onco.cc/trials/nct06198751/), [A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer](https://onco.cc/trials/nct06431490/), [Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors](https://onco.cc/trials/nct07512583/), [Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer](https://onco.cc/trials/nct07008976/), [FUSCC Refractory TNBC Platform Study (FUTURE2.0)](https://onco.cc/trials/nct05749588/), [Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer](https://onco.cc/trials/nct07419880/), [The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer](https://onco.cc/trials/nct06452706/)

---
JSON: https://onco.cc/api/v1/entities/tqb2102.json